Clinical Trial Results:
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.
The PERFORM Study.
An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial).
Summary
|
|
EudraCT number |
2005-003700-10 |
Trial protocol |
BE AT FI ES GB SE HU CZ SI LT IT PT SK DE IE GR |
Global completion date |
31 Mar 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
10 Dec 2016
|
First version publication date |
10 Dec 2016
|
Other versions |
|
Summary report(s) |
Synopsis dated on 17-May-2011 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.